NeoLabsAn index of research-first AI labs
Home / Labs / Chai Discovery
Biology & drug discovery · San Francisco, US · founded 2024

Chai Discovery: who founded it, who funds it

Chai Discovery is a San Francisco AI drug discovery lab founded in 2024 by Joshua Meier, Jack Dent, Jacques Boitreaud and Matthew McPartlon, who came from OpenAI, Stripe, Aqemia and UChicago. What it is building: molecular structure prediction and antibody design (Chai-1, Chai-2), used by Pfizer, Lilly and Novartis. No funding round has been disclosed. It sells access through an API.

Founders
Joshua Meier (ex-OpenAI), Jack Dent (ex-Stripe), Jacques Boitreaud (ex-Aqemia), Matthew McPartlon (ex-UChicago)
Founders from
ex-OpenAI, ex-Stripe, ex-Aqemia, ex-UChicago
Location
San Francisco, US (North America)
Valuation
$3.8B estimate, per source
Raised
· disclosed
Investors
OpenAI, Thrive Capital
What ships
API
Notes
GSK collaboration announced 9 Oct 2026 after a wet-lab evaluation; Endpoints counts it as Chai's sixth pharma partner in nine months.

Sources

News

Investors who back other labs here

  • Thrive Capital also: Physical Intelligence, Essential AI, Isomorphic Labs
  • OpenAI also: Physical Intelligence, Isara, Merge Labs

Same research area